3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Lung Neoplasms
3
Neoplasm Metastasis
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Sarcoma
1
Recurrence
1
Nasopharyngeal Carcinoma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Gallbladder Neoplasms
1
Castration Resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Camurati-Engelmann Syndrome
1
Breast Neoplasms
1
Interventions
Cisplatin
28
Pemetrexed
22
Gemcitabine
10
Nivolumab
9
Carboplatin
9
pembrolizumab
8
tremelimumab
5
durvalumab
5
atezolizumab
5
Radiotherapy
5
Doxorubicin
4
Chemotherapy, Adjuvant
4
Vinorelbine
3
Ipilimumab
3
Bortezomib
3
Bevacizumab
3
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
sodium thiosulfate
2
sargramostim
2
niraparib
2
nintedanib
2
liposomal doxorubicin
2
lenvatinib
2
defactinib
2
cemiplimab
2
cediranib
2
amatuximab
2
Trabectedin
2
Neoadjuvant Therapy
2
Mitomycin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Mesothelioma, Malignant
×
bintrafusp alfa protein, human
×
Clear all
NCT05005429
2025-12-23
BIMES
Fundación GECP
Phase 2
Completed
47 enrolled
9 charts